编者按：第67届美国血液学会（ASH）年会在美国奥兰多落下帷幕。ASH年会是全球规模最大的血液疾病学术会议之一，本届年会上，多家生物医药公司汇报了靶向蛋白降解治疗血液癌症的最新临床试验结果。靶向蛋白降解已经在治疗血液癌症领域得到广泛应用，获批治疗多发 ...

For those and other reasons, targeted oral therapies like Bruton tyrosine kinase inhibitors (BTKis) and the BCL-2 inhibitor ...

默沙东致力于推动血液肿瘤领域的创新与患者关怀。基于肿瘤领域的前沿探索，公司已建立了广泛的临床开发项目，评估多种新型作用机制，力求解决血液肿瘤患者长期未满足的治疗需求。默沙东的研究涵盖多款在研药物，单药或联合其他疗法，覆盖多种血液肿瘤类型。

Discover groundbreaking updates in lymphoma and CLL treatments, including innovative therapies and promising trial results ...

Fixed-duration venetoclax regimens showed non-inferior progression-free survival compared to continuous ibrutinib in CLL ...

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a ...

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival ...

The University of Cincinnati's LDDL trains the next generation of researchers and develops new blood cancer treatments.